There’s a quiet revolution happening inside pharmaceutical supply chains — and most people outside the industry haven’t noticed it yet. Every prescription medicine pack moving through a compliant supply chain today carries a unique digital identity. Every scan, every transfer, every verification event leaves a data trail. The era of anonymous pharmaceutical distribution is over. Here’s what the global data tells us about where serialisation and track-and-trace actually stands in 2026 — and why it matters far more than most manufacturers have yet appreciated.
📦 What We’re Actually Talking About
The terminology gets used loosely, so let’s be precise.
Serialisation means assigning a unique identifier to every individual saleable unit of a pharmaceutical product. Not every batch. Not every shipment. Every. Single. Pack. That identifier — encoded in a 2D Data Matrix barcode — carries the product code, serial number, batch number, and expiry date as a minimum. The result is that every pack leaving a manufacturing facility carries a globally unique identity that can be verified, challenged, and traced independently of every other pack in the same batch.
Track-and-trace is the infrastructure layer that records and communicates the movement of those serialised units through the supply chain — from manufacturing through distribution, wholesale, and dispensing. Serialisation without track-and-trace is a partial solution. A unique identifier on a pack is only valuable if the infrastructure exists to verify it and act on anomalies.
The global regulatory direction — consistently and without exception — is toward end-to-end track-and-trace, not merely pack-level serialisation.
🌍 The Global Regulatory Picture in 2026
European Union
The EU’s Falsified Medicines Directive (FMD), implemented through Delegated Regulation (EU) 2016/161, remains the most comprehensive multi-jurisdiction serialisation framework in operation. Every prescription medicine sold in the EU must carry a unique identifier and an anti-tampering device, verified at the point of dispensing through the European Medicines Verification System (EMVS).
The numbers are striking. The EMVS processes an estimated 15 million verification transactions per day. Since full implementation in February 2019, the system has processed over 28 billion transactions and flagged over 14,000 suspected falsified or diverted packs for investigation. The false alert rate — alerts triggered by legitimate packs due to system or process errors — has declined from 0.4% at launch to approximately 0.06% by 2025. That is a system that has genuinely matured.
India
India’s serialisation programme — mandated by the Central Drugs Standard Control Organisation (CDSCO) — represents the largest serialisation rollout by manufacturing volume anywhere in the world, reflecting India’s position as the world’s largest supplier of generic medicines by volume.
A 2025 CDSCO compliance assessment estimated that approximately 78% of Indian pharmaceutical export manufacturers had achieved full serialisation compliance across all packaging levels. The remaining 22% — concentrated predominantly among smaller manufacturers — still present a material supply chain risk for importing markets with mandatory verification requirements. Given that India supplies an estimated 20% of global generic medicine volume by unit, that gap is not trivial.
China
China’s National Medical Products Administration (NMPA) has built one of the most data-intensive pharmaceutical traceability systems in the world. Unlike the EU’s verification-at-dispensing model, the Chinese system requires transaction-level reporting at every supply chain node — each transfer of custody must be reported to a centralised national platform within a defined timeframe.
By 2025, the NMPA’s pharmaceutical traceability platform was processing an estimated 8 million supply chain transactions per day, covering approximately 95% of prescription medicines sold through formal distribution channels in China.
Saudi Arabia and the GCC
The Saudi Food and Drug Authority (SFDA) has implemented one of the most technically demanding serialisation frameworks outside the EU, requiring full end-to-end track-and-trace including aggregation — the linking of individual serialised packs to their containing shipping cases and pallets. The SFDA framework has become a reference standard progressively adopted across the broader GCC, with the UAE, Kuwait, and Bahrain all advancing comparable requirements through 2025–2026.
📊 The Business Case: Harder Numbers Than You Might Expect
The compliance argument for serialisation investment is straightforward. The business case extends considerably further.
The counterfeit medicine problem that serialisation is designed to address carries an estimated global economic impact of $200 million USD per year in low- and middle-income countries alone — encompassing the direct cost of falsified products, healthcare costs of treatment failures, and the broader erosion of confidence in pharmaceutical supply chains. Europol’s Operation Pangea 2024 seized medicines with an estimated street value of $21 million USD across 116 countries, identifying over 500 websites selling falsified or unlicensed pharmaceutical products.
The operational efficiency data from mature serialisation programmes is equally compelling:
- Recall execution speed across the EU distribution network dropped from 14.2 days pre-FMD to 6.8 days post-implementation — because manufacturers can locate specific serialised units rather than pulling entire batches across entire distribution networks
- Inventory discrepancy rates for distributors using serialisation data fell to 0.8%, compared to 2.3% for batch-level tracking — a direct and measurable working capital efficiency gain
- Returns processing time reduced by an average of 34%, with a significant reduction in fraudulent returns — a persistent source of supply chain loss estimated at $4.5 billion USD annually across the global pharmaceutical industry
And the market access data is now binary in its clarity. A 2025 survey of pharmaceutical procurement officers across 12 major importing markets found that 91% of respondents rated serialisation compliance as a non-negotiable prerequisite for supplier qualification — up from 67% in the equivalent 2022 survey. Compliant product enters the market. Non-compliant product does not.
⚙️ Where Manufacturers Are Still Getting It Wrong
The gap between understanding the requirement and successfully implementing a compliant, operationally robust serialisation programme is where the majority of real-world challenges are concentrated.
Line-level integration is cited as the primary implementation difficulty by 58% of pharmaceutical manufacturers — ahead of regulatory complexity, data management infrastructure, and supply chain partner readiness. The average time from project initiation to validated, production-ready serialisation capability runs 18–24 months for greenfield implementations.
Aggregation data integrity is the most revealing finding. A 2025 analysis of serialisation programme audits across 45 pharmaceutical manufacturing sites found that aggregation data integrity issues were present in 62% of audited sites — compared to 31% for pack-level serialisation data integrity issues. Manufacturers who have successfully implemented pack-level serialisation should not assume that aggregation is a straightforward extension of existing capability. It consistently is not.
Supply chain partner readiness is the weakest link that most manufacturers underestimate. 39% of fully compliant manufacturers cite the serialisation capability of their third-party logistics providers and smaller wholesale distributors as their primary operational bottleneck. A serialisation programme that functions flawlessly at the manufacturing site generates no supply chain visibility benefit if the downstream logistics partners cannot process the data.
💡 What the Leaders Are Doing Differently
The manufacturers navigating this landscape most successfully share a consistent set of strategic orientations.
They design for the most demanding market requirement in their portfolio, not the least. Systems designed to meet minimum requirements will require costly re-engineering as additional markets are added or existing requirements are upgraded.
They treat data management as the core competency, not the hardware. The serialisation printers and cameras are commodities. The data management infrastructure that captures, validates, and communicates serialisation data across the supply chain is where the long-term advantage resides.
They build supply chain partner capability into the programme scope from day one — not as an afterthought once the manufacturing site is compliant. And they plan for regulatory evolution, not regulatory stability. The global serialisation landscape has been in continuous evolution for a decade and shows no signs of stabilising.
Serialisation and track-and-trace have moved from the compliance agenda to the strategic agenda. The data is clear, the regulatory direction is unambiguous, and the manufacturers who have invested in genuine end-to-end capability are already operating with advantages — in market access, supply chain resilience, and commercial credibility — that their less-prepared competitors are only beginning to quantify.
